15% OFF Semax – 10mg/vial (Research Use Only)
Semax, a synthetic heptapeptide based on an ACTH fragment, studied in neurotrophin (BDNF/NGF) and melanocortin signalling research. Supplied for laboratory research and identification purposes only.
Availability: In stock
3–4 vials — 5% off · 5–9 vials — 10% off · 10+ vials — 15% off
Applied automatically in the cart. Combines with a discount code up to 20% off in total, and stacks on top of the subscription discount.
Research Disclaimer: All products currently listed on this site are for research purposes only.
- Studied for BDNF and NGF gene expression in hippocampus and prefrontal cortex models
- Developed at the Russian Academy of Sciences; studied in ischaemic stroke recovery
- No stimulant mechanism or receptor downregulation documented in the published literature
- Derived from the ACTH(4–7) sequence with a C-terminal Pro-Gly-Pro extension for metabolic stability
- No receptor competition with other research peptides documented
Mechanism of Action
Semax is a heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4–7) sequence, modified with a proline-glycine-proline C-terminal extension for metabolic stability. Published work reports upregulation of BDNF and NGF gene expression in the hippocampus and prefrontal cortex, effects on dopaminergic and serotonergic neurotransmission, and neuroprotective effects against ischaemic and oxidative stress. The Pro-Gly-Pro extension confers resistance to enzymatic degradation.
Research Overview
Clinical studies in Russia evaluated Semax in acute ischaemic stroke recovery, reporting changes in neurological deficit scores versus placebo. Cognitive studies report effects on attention, working memory and processing speed. BDNF upregulation has been observed within hours of administration, with expression reported to persist for several days. This body of work has limited independent replication outside Russia.
Research & Stack Notes
Semax and Selank are frequently examined together in the published cognitive literature, acting on different pathways. No receptor competition with longevity or metabolic research compounds is documented.
Educational purposes only. Research use. Not evaluated by the FDA.
Overview
Semax is a synthetic nootropic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, based on the ACTH(4-10) core fragment extended with a Pro-Gly-Pro C-terminal tripeptide for improved metabolic stability. Originally studied for cerebrovascular and neuroprotective applications, Semax has generated a published research base spanning BDNF upregulation, dopaminergic and serotonergic system modulation, ischemia-reperfusion research, and cognitive function biomarker studies in rodent models. It holds regulatory approval in Russia and Ukraine as a nootropic peptide drug.
What It Is
Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, MW approximately 779 Da, CAS number 80714-61-0. It is a structural analogue of ACTH(4-7) (Met-Glu-His-Phe) with the C-terminal Pro-Gly-Pro extension borrowed from the Selank research program to confer enzymatic stability. Semax does not bind melanocortin receptors at pharmacologically relevant concentrations but has been shown in published research to upregulate BDNF and NGF expression, modulate dopamine system markers, and affect serotonin transporter activity.
Key Research Applications
- BDNF and NGF upregulation in cortical and hippocampal tissue research
- Cerebrovascular research — ischemia-reperfusion injury and neuroprotection modeling
- Dopaminergic system modulation and D1/D2 receptor expression studies
- Serotonin transporter (SERT) and serotonergic signaling research
- Cognitive function biomarker and memory consolidation studies in rodent models
- ACTH fragment pharmacology without adrenocortical activation
- Nootropic peptide comparative pharmacology vs. Selank and other ACTH-derived peptides
- Stroke, traumatic brain injury, and hypoxia preclinical modeling studies
Technical Specifications
| Amino Acids | 7 (Met-Glu-His-Phe-Pro-Gly-Pro) |
| Molecular Weight | ~779 Da |
| CAS Number | 80714-61-0 |
| Parent Structure | ACTH(4-7) + Pro-Gly-Pro extension |
| Purity | ≥98% (supplier specification) |
| Form | Lyophilized powder |
| Vial Size | 10mg |
| Storage | −4 °F long-term |
FOR RESEARCH USE ONLY. Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.
Not sure which compounds fit your research? Browse the Research Hub →
Regulatory Status Note
On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was not recommended. FDA’s own briefing documents had recommended against all seven.
A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. Source: FDA Advisory Committee Calendar. Last reviewed: August 17, 2026.
- Processing: Orders ship within 1–2 business days
- Domestic delivery: 3–5 business days via USPS Priority / UPS Ground
- Free shipping on orders over $100
- Temperature handling: Cold-chain packaging available on request for lyophilized peptides
- Tracking: Emailed automatically at time of dispatch
- Store lyophilized (dry) peptides at −4 °F for long-term stability
- Protect from light and moisture at all times
- Do not freeze
- Where the Storage row in the product specification above differs, follow the specification
Frequently Asked Questions
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) based on a fragment of ACTH. It has been studied for effects on BDNF and NGF expression and on melanocortin signalling. It is approved as a medicine in Russia; it is not FDA-approved. Portal to Wellness does not publish protocols, combinations or quantities, and nothing on this page is a recommendation for use.
Pairs Well With
Related research products
Reviews
There are no reviews yet.